Ind-Swift Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE915B01019
  • NSEID: INDSWFTLAB
  • BSEID: 532305
INR
162.80
1.2 (0.74%)
BSENSE

Jun 10, 03:30 PM

BSE+NSE Vol: 14.19 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Part of MojoOne Strategy
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
NGL Fine Chem
Fredun Pharma
Lincoln Pharma.
Hester Bios
Amrutanjan Healt
Ind-Swift Labs.
Syncom Formul.
Windlas Biotech
Beta Drugs Ltd
Shukra Pharma.
Jagsonpal Pharma

Why is Ind-Swift Laboratories Ltd ?

1
Weak Long Term Fundamental Strength with a -138.33% CAGR growth in Operating Profits over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.67
  • The company has been able to generate a Return on Equity (avg) of 7.99% signifying low profitability per unit of shareholders funds
2
With a growth in Net Sales of 22.82%, the company declared Very Positive results in Mar 26
  • The company has declared positive results for the last 3 consecutive quarters
  • PBT LESS OI(Q) At Rs 14.89 cr has Grown at 47.13%
  • NET SALES(Q) Highest at Rs 169.79 cr
  • PBDIT(Q) Highest at Rs 20.58 cr.
3
Risky - Negative Operating Profits
  • The company has recorded a negative EBIT of Rs. -0.79 cr
  • Over the past year, while the stock has generated a return of 67.23%, its profits have risen by 369.1% ; the PEG ratio of the company is 0.1
  • The stock is trading risky as compared to its average historical valuations
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Ind-Swift Labs. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ind-Swift Labs. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Ind-Swift Labs.
67.23%
1.31
51.18%
Sensex
-10.21%
-0.78
13.06%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-6.82%
EBIT Growth (5y)
-138.33%
EBIT to Interest (avg)
1.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.67
Tax Ratio
15.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
13.88%
ROCE (avg)
8.57%
ROE (avg)
7.99%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
29
Industry P/E
34
Price to Book Value
1.03
EV to EBIT
-1003.63
EV to EBITDA
33.65
EV to Capital Employed
1.05
EV to Sales
1.60
PEG Ratio
0.13
Dividend Yield
NA
ROCE (Latest)
-0.08%
ROE (Latest)
3.61%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company
PBT LESS OI(Q)

At Rs 14.89 cr has Grown at 47.13%

NET SALES(Q)

Highest at Rs 169.79 cr

PBDIT(Q)

Highest at Rs 20.58 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 12.12%

PAT(Q)

Highest at Rs 20.26 cr.

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Ind-Swift Labs.

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 14.89 cr has Grown at 47.13%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 20.26 cr has Grown at 44.1%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 169.79 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 169.79 cr has Grown at 22.82%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 20.58 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 12.12%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 14.89 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 20.26 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)